West and colleagues showed that high levels of oncostatin M (OSM), its receptor (OSMR) and the related transcriptional modules in inflamed gut of IBD patients were associated with non-response to anti-TNF therapy (West et al., 2017). Here, OSM is linked to inflammatory bowel disease.